(Journal Article): Insulinotropic and Anti-Inflammatory Effects of Rosiglitazone in Experimental Autoimmune Diabetes
 
Awara WM, El-Sisi AE, Mohamed El-Refaei M, El-Naa MM, El-Desoky K (Department of Pharmacology/Toxicology, College of Pharmacy, University of Tanta, Egypt, wagawara(at)yahoo.com )
 
IN: Rev Diabetic Stud 2005; 2(3):146-156
Impact Factor(s) of Rev Diabetic Stud: 0.125 (2006)

Fulltext:    HTML  PDF

ABSTRACT: Cytokines and nitric oxide (NO) are involved in the pathogenesis of autoimmune diabetes mellitus (DM). Rosiglitazone is an insulin-sensitizing drug that is a ligand for the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPAR-γ). The anti-inflammatory and immunomodulating properties of PPAR-γ have been documented. The aim of this study is to investigate the effectiveness of rosiglitazone in autoimmune DM and to clarify the possible mechanism(s) involved. Autoimmune DM was induced in adult male Balb/c mice by co-administration of cyclosporin A and multiple low doses of streptozotocin. Diabetic mice were treated daily with rosiglitazone (7 mg/kg, p.o.) for 21 days. Blood glucose level (BGL), serum insulin level and pancreatic levels of tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ) and NO were measured. Histopathological examination and immunohistochemical determination of CD4 and CD8 T lymphocytes in the pancreatic islets were performed. In addition, analysis of pancreatic protein expression was carried out. The results showed that rosiglitazone treatment resulted in a significant decrease in the BGL and the pancreatic levels of TNF-α, IFN-γ and NO compared to diabetic mice. The serum insulin level was significantly increased after rosiglitazone treatment compared to diabetic mice. The destroyed pancreatic islets were regenerated and became free from both CD4 and CD8 T cells after treatment. Furthermore, many changes in pancreatic protein expression were observed. These results suggest that rosiglitazone has a beneficial effect in the treatment of autoimmune diabetes, an effect that seemed to be a secondary consequence of its anti-inflammatory and immunomodulating properties and might be reflected at the level of protein expression.

TYPE OF PUBLICATION: Original article

REFERENCES:

1. Gepts W, In't Veld PA. Islet morphological changes. Diabetes Metab Rev 1987. 3:859-872.
2. Rabinovitch A. Role of cell-mediated immunity and cytokines in the pathogenesis of type 1 diabetes mellitus. In: Le Roith D, Taylor SI, Olefsky JM. Diabetes Mellitus a Fundamental and Clinical Text 2000. pp 383-398.
3. Rabinovitch A, Suarez-Pinzon WL. Role of cytokines in the pathogenesis of autoimmune diabetes mellitus. Rev Endocr Metab Disord 2003. 4:291-299.
4. Major CD, Gao ZY, Wolf BA. Activation of the sphingomyelinase/ceramide signal transduction pathway in insulin-secreting beta-cells: role in cytokine induced beta-cell death. Diabetes 1999. 48:1372-1380.
5. Lehmann PV, Sercerz EE, Forsthuber T, Dayan CM, Gammon G. Determinant spreading and the dynamics of the autoimmune T cell repertoire. Immunol Today 1993. 14:203-207.
6. Faust A, Rothe H, Schade U, Lampeter E, Kolb H. Primary nonfunction of islet grafts in autoimmune diabetic nonobese diabetic mice is prevented by treatment with interleukin-4 and interleukin-10. Transplantation 1996. 62:648-652.
7. Suarez-Pinzon W, Sorensen O, Bleackley RC, Elliott JF, Rajotte RV, Rabinovitch A. β-cell destruction in NOD mice correlates with Fas (CD95) expression on β-cells and proinflammatory cytokines expression in islets. Diabetes 1999. 48:21-28.
8. Like AA, Rossini AA. Streptozotocin induced pancreatic insulitis: new model of diabetes mellitus. Science 1976. 193:27-54.
9. Kolb H, Kroncke KD. Lesson from the low-dose streptozotocin model in mice. Diabetes Rev 1993. 1: 16-26.
10. Roep BO, Atkinson M, von Herrath M. Satisfaction (not) Guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol 2004. 4:989-997.
11. Snadberg JO, Anersson A, Eizirik DL, Sandler S. Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice. Biochem Biophys Res Commun 1994. 202:543-548.
12. Herold KC, Vezys V, Sun Q, Viktora D, Seung E, Reiner S, Brown D. Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol 1996. 156:3521-3527.
13. Holdstad M, Sandler S. A transcriptional inhibitor of TNF-α prevents diabetes induced by multiple low-doses streptozotocin injections in mice. J Autoimmun 1996. 156:3521-3527.
14. Kolb H, Kicscel U, Kroncke KD, Kolb-Bachofen V. Suppression of low-dose streptozotocin induced diabetes in mice by administration of nitric oxide synthase inhibitor. Life Sci 1991. 49:L213-L217.
15. Flodstrom M, Tyrberg B, Eizirik DL, Sandler S. Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes. Diabetes 1999. 48:706-713.
16. Cvetkovic I, Al-Abed Y, Miljkovic D, Maksiovic –Ivanic D, Roth J, Bacher M, Lan H, Nicoletti F, Stosic-Grujicic S. Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 2005. 146(7):2942-2951.
17. Fraser RB, Rowden G, Colp P, Wright JR. Immunophenotyping of insulitis in control and essential fatty acid deficient mice treated with multiple low-dose streptozotocin. Diabetologia 1997. 40:1263-1268.
18. Wright JR, Fraser RB, Kapoor S, Cook HW. Essential fatty acid deficiency prevents multiple low-dose streptozotocin-induced diabetes in naive and cyclosporine-treated low-responder murine strains. Acta Diabetologica 1995. 32:125-130.
19. Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinedione. J Clin Invest 2000. 106:1305-1307.
20. Noble J, Baerlocher MO, Silverberg J. Management of type 2 diabetes mellitus. Role of thiazolidinediones. Can Fam Physician 2005. 51:683-687.
21. Desvergne B and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Reviews 1999. 20:649-688.
22. Delerive P, Fruchart J-C, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001. 169:453-459.
23. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Maffia P, Patel NS, Di Paola R, Ialenti A, Genovese T, Chatterjee PK, et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol 2004. 483(1):79-93.
24. Hasegawa H, Takano H, Zou Y, Qin Y, Hizukuri K, Odaka K, Toyozaki T, Komuro I. Pioglitazone, a peroxisome proliferator-activated receptor gamma activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance. J Mol Cell Cardiol 2005. 38(2):257-265.
25. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol 1969. 22(2):158-161.
26. Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001. 5(1):62-71.
27. Laemmli AS. Cleavage of structural protein during the assembly of the deep bacterophage CT4. Nature 1970. 227:680-684.
28. Somoza N, Vargas F, Roura-Mir C, Vives-Pi M, Fenandez Figueras MT, Ariza A, Gomis R, Bragado R, Marti M, Jaraquemada D, Pujol-Borrell R. Pancreas in recent onset insulin-dependent diabetes mellitus. J Immunol 1994. 153:1360-1377.
29. Serreze DV, Gaskins HR, Leiter EH. Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. J Immunol 1993. 150:2534-2543.
30. Beales PE, Liddi R, Giorgini AE, Signore A, Procaccini E, Batchelor K, Pozzilli P. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. Eur J Pharmacol 1998. 357:221-225.
31. Beales PE and Pozzilli P. Thiazolidinediones for the prevention of diabetes in non-obese dependent (NOD) mouse: implications for human type 1 diabetes. Diabetes Metab Res Rev 2002. 18:114-117.
32. Takamura T, Andro H, Nagai Y, Yamashita H, Nohora E, kobayashi K. Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes. Diabetes Res Clin Pract 1999. 44 (2):107-114.
33. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. PPAR-γ and PPAR-δ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages. PNAS 2003. 100(11):6712-6717.
34. Wang YL, Frauwirth KA, Rangwala SM, Lazar MA, Thompson CB. Thiazolidinedione activation of Peroxisome proliferator-activated receptor γ can enhance mitochondrial potential and promote cell survival. J Biol Chem 2002. 277(35):31781-31788.
35. Daynes RA and Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002. 2:748-759.
36. Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, Derijard B, Desvergne B, Wahli W, Chambon P. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer: a basis for new therapeutic strategies. J Exp Med 2001. 193:827-838.
37. Cuzzocrea S, Mazzon E, Dugo L, Patel NS, Serraino I, Di Paola R, Genovese T, Britti D, De Maio M, Caputi AP, et al. Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2003. 48(12):3544-3556.
38. Ito H, Nakano A, Kinoshita M, Matsumori A. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest 2003. 83(12):1715-1721.
39. Marx N, Kehrle B, Kohlhammer K Grub M, Koenig W, Hombach V, Libby P, Plutzky J. PPAR activators as anti-inflammatory mediators in human T lymphocytes: implication for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002. 90:703-710.
40. Papaccio G, Ammendole E, Pisanti FA. Nicotinamide decreases MHC class II but not MHC class I expression and increases intercellular adhesion molecule-1 structures in non-obese diabetic mouse pancreas. J Endocrinol 1999. 160:389-400.
41. Campbell IL, Oxbrow L, Harrison LC. Interferon-γ: pleiotropic effects on a rat pancreatic beta cell line. Mol Cell Endocrinol 1987. 52:161-167.
42. Defilippi P, Poupart P, Tavernier J, Fiers W, Contant W. Induction and regulation of mRNA encoding 26-kDa protein in human cell line treated with recombinant human tumor necrosis factor. Proc Natl Acad Sci USA 1987. 84:4557-4561.
43. Dealtry GB, Naylor MS, Fiers W, Balkwill FR. DNA fragmentation and cytotoxicity caused by tumour necrosis factor is enhanced by Interferon-γ. Eur J Immunol 1987. 17:689-693.
44. Campbell IL, Iscaro A, Harrison LC. IFN-γ and tumor necrosis factor-α: cytotoxicity to murine islets of langerhans. J Immunol 1988. 141:2325-2329.
45. Campbell IL, Wong GH, Schrader JW, Harrison LC. Interferon-γ enhances the expression of the major histocompatibility class 1 antigens on mouse pancreatic beta cells. Diabetes 1985. 34:1205-1209.
46. Campbell IL, Oxbrow L, West J, Harrison LC. Regulation of MHC protein expression in pancreatic beta cells by interferon-γ and tumour necrosis factor-α. Mol Endocrinol 1988. 2:101-107.
47. Hong G, Davis B, Khatoon N, Baker SF, Brown J. PPAR gamma-dependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNF alpha secretion is not mediated by PTEN regulation. Biochem Biophys Res Commun 2003. 303(3):782-787.
48. Miller BJ, Appel MC, O'Neil J, Wicker LS. Both the LYT-2+ and L3T4+ T cell subsets are required for transfer of diabetes in non obese diabetic mice. J Immunol 1988. 140:52-58.
49. Thomas HE, Darwiche R, Corbett JA, Kay TW. Interleukin-1 plus gamma-interferon-induced pancreatic beta-cell dysfunction is mediated by beta-cell nitric oxide production. Diabetes 2002. 51(2):311-316.
50. Fehsel K, Kroncke KD, Kolb-Bachofen V. The action of NO and its role in autoimmune diabetes mellitus. Res Immunol 1995. 146:711-715.
51. Dubois M, Pattou F, Kerr-Conte J, Vandewalle B, Desreumaux P, Auwerx J, Schoonjans K, and Lefebvre J. Expression of peroxisome proliferators-activated receptor-γ (PPAR-γ) in normal human pancreatic islet cells. Diabetologia 2000. 43:1165-1169.
52. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J. Activation of proliferators-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998. 273(40):25573-22580.
53. Andersen HU, Larsen PM, Fey SJ, Karlsen AE, Mandrup-Poulsen T, Nerup J. Two-dimensional gel electrophoresis of rat islets proteins: interleukin-1 beta induced changes in protein expression are reduced by L-arginine depletion and nicotinamide. Diabetes 1995. 44:400-407.
54. Karlsen AE, Andersen HU, Vissing H, Mose Larsen P, Fey SJ, Cuartero BG, Madsen OD, Petersen JS, Mortensen SB, Mandrup-Poulsen T, et al. Cloning and expression of cytokine inducible nitric oxide synthase cDNA from rat islets of Langerhans. Diabetes 1995. 44:753-758.
55. Larsen PM, Fey SJ, Larsen MR, Nawrocki A, Andersen HU, Kahler H, Heilmann C, Voss MC, Roepstorff P, Pociot F, et al. Proteome analysis of interleukin-1β-induced changes in protein expression in rat islets of langerhans. Diabetes 2001. 50:1056-1063.
56. Eizirik DL, Bjorklund A, Welsh N. Interleukin-1-induced expression of nitric oxide synthase in insulin producing cells is preceded by c-fos induction and depends on gene transcription and protein synthesis. FEBS Lett 1993. 317:62-66.
57. Sanchez J-C, Converset V, Nolan A, Schmid G, Wang S, Heller M, Sennitt MV, Hochstrasser F, Cawthorne MA. Effect of rosiglitazone on the differential expression of diabetes-associated proteins in pancreatic islets of C57Bl/6 lep/lep mice. Molecular and Cellular Proteomics 2002. 1:509-516.
58. Rieusset J, Chambrier C, Bouzakri K, Dusserre E, Auwerx J, Riou JP, Laville M, Vidal H. The expression of the p85α subunit of phosphatidylinositol 3-Kinase is induced by activation of the peroxisome proliferator-activated receptor-γ in human adipocytes. Diabetologia 2001. 44:544-554.